News ReleaseView printer-friendly version
Quidel to Present at UBS Global Life Sciences on September 27
SAN DIEGO, Sep 20, 2006 (BUSINESS WIRE) -- Quidel Corporation (NASDAQ:QDEL), a leading provider of point-of-care (POC) rapid diagnostic tests, today announced that it will present at the UBS Global Life Sciences Conference to be held September 25-28, 2006 at the Grand Hyatt New York Hotel.
The Company is scheduled to speak on Wednesday, September 27, 2006, at 9:30 a.m. Eastern time (6:30 a.m. Pacific time) and will discuss its strategic initiatives, business developments and market opportunities.
Investors may access a live audio Internet webcast via the Investor Information section of the Company's Web site at www.quidel.com. A replay of the presentation and Q&A will be available for 14 days following the conference at the above Web address.
Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue(R), the portfolio currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, Fecal Occult Blood, Strep A, pregnancy, bacterial vaginosis, infectious mononucleosis, H. pylori and chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit. For more information, visit www.quidel.com, www.flutest.com, or www.colorectal-test.com.
SOURCE: Quidel Corporation
Paul E. Landers, 858-552-7962 (Chief Financial Officer)
Lippert/Heilshorn & Associates
Don Markley or Bruce Voss, 310-691-7100